Log in
NYSE:HRC

Hill-Rom Competitors

$97.55
+0.06 (+0.06 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$97.00
Now: $97.55
$98.49
50-Day Range
$82.91
MA: $91.53
$97.49
52-Week Range
$72.29
Now: $97.55
$117.68
Volume739,085 shs
Average Volume641,452 shs
Market Capitalization$6.52 billion
P/E Ratio31.47
Dividend Yield0.90%
Beta0.62

Competitors

Hill-Rom (NYSE:HRC) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying HRC stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Hill-Rom, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and Hill-Rom (NYSE:HRC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares Abbott Laboratories and Hill-Rom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20

Abbott Laboratories has higher revenue and earnings than Hill-Rom. Hill-Rom is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

63.9% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 86.3% of Hill-Rom shares are owned by institutional investors. 1.7% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.7% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Abbott Laboratories and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Hill-Rom7.05%25.48%8.66%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Abbott Laboratories and Hill-Rom, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
Hill-Rom01602.86

Abbott Laboratories presently has a consensus price target of $115.3750, indicating a potential upside of 5.59%. Hill-Rom has a consensus price target of $116.2857, indicating a potential upside of 19.21%. Given Hill-Rom's stronger consensus rating and higher probable upside, analysts plainly believe Hill-Rom is more favorable than Abbott Laboratories.

Dividends

Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. Hill-Rom pays an annual dividend of $0.88 per share and has a dividend yield of 0.9%. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Hill-Rom pays out 17.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 48 consecutive years and Hill-Rom has increased its dividend for 1 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Summary

Abbott Laboratories beats Hill-Rom on 10 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Hill-Rom (NYSE:HRC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares Medtronic and Hill-Rom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20

Medtronic has higher revenue and earnings than Hill-Rom. Hill-Rom is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 86.3% of Hill-Rom shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 0.7% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Medtronic and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
Hill-Rom7.05%25.48%8.66%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Medtronic and Hill-Rom, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
Hill-Rom01602.86

Medtronic presently has a consensus price target of $118.1538, indicating a potential upside of 6.47%. Hill-Rom has a consensus price target of $116.2857, indicating a potential upside of 19.21%. Given Hill-Rom's stronger consensus rating and higher probable upside, analysts plainly believe Hill-Rom is more favorable than Medtronic.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Hill-Rom pays an annual dividend of $0.88 per share and has a dividend yield of 0.9%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Hill-Rom pays out 17.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has increased its dividend for 43 consecutive years and Hill-Rom has increased its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Volatility & Risk

Medtronic has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Summary

Medtronic beats Hill-Rom on 10 of the 18 factors compared between the two stocks.

Stryker (NYSE:SYK) and Hill-Rom (NYSE:HRC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Volatility & Risk

Stryker has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Hill-Rom pays an annual dividend of $0.88 per share and has a dividend yield of 0.9%. Stryker pays out 27.8% of its earnings in the form of a dividend. Hill-Rom pays out 17.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 1 consecutive years and Hill-Rom has increased its dividend for 1 consecutive years.

Insider and Institutional Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 86.3% of Hill-Rom shares are owned by institutional investors. 6.8% of Stryker shares are owned by company insiders. Comparatively, 0.7% of Hill-Rom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Stryker and Hill-Rom's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Hill-Rom7.05%25.48%8.66%

Valuation and Earnings

This table compares Stryker and Hill-Rom's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20

Stryker has higher revenue and earnings than Hill-Rom. Hill-Rom is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Stryker and Hill-Rom, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Hill-Rom01602.86

Stryker presently has a consensus price target of $221.44, indicating a potential downside of 4.97%. Hill-Rom has a consensus price target of $116.2857, indicating a potential upside of 19.21%. Given Hill-Rom's stronger consensus rating and higher probable upside, analysts plainly believe Hill-Rom is more favorable than Stryker.

Summary

Stryker beats Hill-Rom on 12 of the 17 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Risk and Volatility

Hill-Rom has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

86.3% of Hill-Rom shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Hill-Rom and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.05%25.48%8.66%
Intuitive Surgical24.45%12.08%10.44%

Earnings and Valuation

This table compares Hill-Rom and Intuitive Surgical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Intuitive Surgical has higher revenue and earnings than Hill-Rom. Hill-Rom is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Hill-Rom and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
Intuitive Surgical371202.41

Hill-Rom presently has a consensus target price of $116.2857, indicating a potential upside of 19.21%. Intuitive Surgical has a consensus target price of $718.2778, indicating a potential downside of 0.11%. Given Hill-Rom's stronger consensus rating and higher probable upside, research analysts clearly believe Hill-Rom is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Hill-Rom on 11 of the 14 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Risk & Volatility

Hill-Rom has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Dividends

Hill-Rom pays an annual dividend of $0.88 per share and has a dividend yield of 0.9%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Hill-Rom pays out 17.3% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Hill-Rom has raised its dividend for 1 consecutive years and Becton, Dickinson and has raised its dividend for 49 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional and Insider Ownership

86.3% of Hill-Rom shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 0.7% of Hill-Rom shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Hill-Rom and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.05%25.48%8.66%
Becton, Dickinson and5.11%13.30%5.60%

Earnings & Valuation

This table compares Hill-Rom and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Hill-Rom. Hill-Rom is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Hill-Rom and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
Becton, Dickinson and07712.60

Hill-Rom presently has a consensus target price of $116.2857, indicating a potential upside of 19.21%. Becton, Dickinson and has a consensus target price of $280.2857, indicating a potential upside of 22.67%. Given Becton, Dickinson and's higher probable upside, analysts clearly believe Becton, Dickinson and is more favorable than Hill-Rom.

Summary

Becton, Dickinson and beats Hill-Rom on 11 of the 18 factors compared between the two stocks.

Hill-Rom (NYSE:HRC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Risk and Volatility

Hill-Rom has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Institutional and Insider Ownership

86.3% of Hill-Rom shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Hill-Rom and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hill-Rom7.05%25.48%8.66%
Edwards Lifesciences18.18%29.00%18.10%

Earnings and Valuation

This table compares Hill-Rom and Edwards Lifesciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hill-Rom$2.91 billion2.24$152.20 million$5.0819.20
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Hill-Rom. Hill-Rom is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Hill-Rom and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hill-Rom01602.86
Edwards Lifesciences251302.55

Hill-Rom presently has a consensus target price of $116.2857, indicating a potential upside of 19.21%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given Hill-Rom's stronger consensus rating and higher probable upside, research analysts clearly believe Hill-Rom is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats Hill-Rom on 10 of the 14 factors compared between the two stocks.


Hill-Rom Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.